Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 2
1998 2
2004 1
2006 1
2008 1
2009 3
2010 1
2011 3
2012 8
2013 9
2014 7
2015 6
2016 6
2017 2
2018 7
2019 4
2020 5
2021 4
2022 5
2023 3
2024 6
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Platzbecker U, et al. Among authors: jonasova a. Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048786 Clinical Trial.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Platzbecker U, et al. Among authors: jonasova a. Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10. Lancet. 2023. PMID: 37311468 Clinical Trial.
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
Della Porta MG, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U. Della Porta MG, et al. Among authors: jonasova a. Lancet Haematol. 2024 Sep;11(9):e646-e658. doi: 10.1016/S2352-3026(24)00203-5. Epub 2024 Jul 19. Lancet Haematol. 2024. PMID: 39038479 Clinical Trial.
Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.
Weinbergerová B, Mayer J, Kabut T, Sperr WR, Števková J, Jonášová A, Čerňan M, Herndlhofer S, Oravcová I, Šrámek J, Novák J, Štěpánová R, Szotkowski T, Drgoňa L, Žák P, Valent P. Weinbergerová B, et al. Among authors: jonasova a. Br J Haematol. 2024 Nov;205(5):1746-1750. doi: 10.1111/bjh.19670. Epub 2024 Jul 23. Br J Haematol. 2024. PMID: 39044120
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Kubasch AS, Giagounidis A, Metzgeroth G, Jonasova A, Herbst R, Diaz JMT, De Renzis B, Götze KS, Huetter-Kroenke ML, Gourin MP, Slama B, Dimicoli-Salazar S, Cony-Makhoul P, Laribi K, Park S, Jersemann K, Schipp D, Metzeler KH, Tiebel O, Sockel K, Gloaguen S, Mies A, Chermat F, Thiede C, Sapena R, Schlenk RF, Fenaux P, Platzbecker U, Adès L. Kubasch AS, et al. Among authors: jonasova a. Leukemia. 2022 Oct;36(10):2519-2527. doi: 10.1038/s41375-022-01669-z. Epub 2022 Sep 7. Leukemia. 2022. PMID: 36071100 Free PMC article.
Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways.
Minařík L, Pimková K, Kokavec J, Schaffartziková A, Vellieux F, Kulvait V, Daumová L, Dusilková N, Jonášová A, Vargová KS, Králová Viziová P, Sedláček R, Zemanová Z, Stopka T. Minařík L, et al. Among authors: jonasova a. Cells. 2022 Jan 11;11(2):223. doi: 10.3390/cells11020223. Cells. 2022. PMID: 35053339 Free PMC article.
Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa.
Jonasova A, Sotakova S, Belohlavkova P, Minarik L, Stopka T, Jonas JJ, Aghova T, Zemanova Z. Jonasova A, et al. Front Oncol. 2024 Oct 2;14:1398331. doi: 10.3389/fonc.2024.1398331. eCollection 2024. Front Oncol. 2024. PMID: 39416466 Free PMC article.
Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower-risk myelodysplastic neoplasms.
Kaisrlikova M, Kundrat D, Koralkova P, Trsova I, Lenertova Z, Votavova H, Merkerova MD, Krejcik Z, Vesela J, Vostry M, Simeckova R, Markova MS, Lauermannova M, Jonasova A, Cermak J, Divoky V, Belickova M. Kaisrlikova M, et al. Among authors: jonasova a. Int J Cancer. 2024 May 1;154(9):1652-1668. doi: 10.1002/ijc.34834. Epub 2024 Jan 5. Int J Cancer. 2024. PMID: 38180088
Improved hematopoietic stem cell transplantation upon inhibition of natural killer cell-derived interferon-gamma.
Lobo de Figueiredo-Pontes L, Adamcova MK, Grusanovic S, Kuzmina M, Aparecida Lopes I, Fernandes de Oliveira Costa A, Zhang H, Strnad H, Lee S, Moudra A, Jonasova AT, Zidka M, Welner RS, Tenen DG, Alberich-Jorda M. Lobo de Figueiredo-Pontes L, et al. Among authors: jonasova at. Stem Cell Reports. 2021 Aug 10;16(8):1999-2013. doi: 10.1016/j.stemcr.2021.06.008. Epub 2021 Jul 8. Stem Cell Reports. 2021. PMID: 34242616 Free PMC article.
ASXL1 gene alterations in patients with isolated 20q deletion.
Brezinova J, Sarova I, Svobodova K, Lhotska H, Ransdorfova S, Izakova S, Pavlistova L, Lizcova L, Skipalova K, Hodanova L, Markova J, Zemanova Z, Cermak J, Jonasova A, Michalova K. Brezinova J, et al. Among authors: jonasova a. Neoplasma. 2019 Jul 23;66(4):627-630. doi: 10.4149/neo_2018_181010N754. Neoplasma. 2019. PMID: 30868899
79 results